The Relationship Of Covid-19 And Chronic Disorders In Maxico.
Keywords:
A risk factor for chronic degenerative disease is the Covid-19 virus.Abstract
Background:The COVID-19 pandemic has disproportionately affected individuals with chronic degenerative diseases, contributing to increased morbidity and mortality worldwide. In Mexico, where such conditions are prevalent, understanding their association with COVID-19 outcomes is crucial.
Objective:To identify the risk factors associated with morbidity and mortality due to COVID-19 among individuals of different age groups suffering from chronic degenerative diseases in Mexico during 2020.
Methods:A systematic literature review was conducted to address the research question. Specific descriptors were used to search the DeCS and MeSH platforms, and strategies were developed to retrieve relevant studies from major health science databases, including Google Scholar, PubMed, and SciELO. The search spanned three months.
Results:Eleven relevant publications were identified. The findings revealed that obesity was the most significant predictor of COVID-19 morbidity and mortality, followed by diabetes, hypertension, and chronic kidney failure. The population most affected included men over sixty years old, particularly from the states of Mexico, Veracruz, Oaxaca, and Guanajuato. Approximately 73% of patients exhibited mild outpatient symptoms. However, individuals with cerebrovascular disease, chronic kidney disease, bronchial asthma, and elevated triglyceride or cholesterol levels were at higher risk of death.
Conclusion:Hypertension, diabetes, obesity, and cardiovascular diseases are the most prevalent chronic degenerative conditions associated with adverse COVID-19 outcomes. The presence of these comorbidities significantly increases the risk of morbidity and mortality in the Mexican population..
Downloads
References
[1] Acevedo-Sánchez, G., Mora-Aguilera, G., Coria-Contreras, J. J., & Álvarez-Maya, I. (2023). Were metabolic and other chronic diseases the driven onset epidemic forces of COVID-19 in Mexico? Frontiers in public health, 11, 995602.
[2] Angulo-Zamudio, U. A., Martinez-Villa, F. M., Leon-Sicairos, N., Flores-Villasenor, H., Velazquez-Roman, J., Campos-Romero, A., Alcantar-Fernandez, J., Urrea, F., Muro-Amador, S., & Medina-Serrano, J. (2021). Analysis of Epidemiological and Clinical Characteristics of COVID-19 in Northwest Mexico and the Relationship Between the Influenza Vaccine and the Survival of Infected Patients. Frontiers in public health, 9, 570098.
[3] Ashktorab, H., Pizuomo, A., González, N. A. F., Villagrana, E. D. C., Herrera-Solís, M. E., Cardenas, G., Zavala-Alvarez, D., Oskrochi, G., Awoyemi, E., & Adeleye, F. (2021). A comprehensive analysis of COVID-19 impact in Latin America. Research Square.
[4] Bello-Chavolla, O. Y., Bahena-López, J. P., Antonio-Villa, N. E., Vargas-Vázquez, A., González-Díaz, A., Márquez-Salinas, A., Fermín-Martínez, C. A., Naveja, J. J., & Aguilar-Salinas, C. A. (2020). Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. The Journal of Clinical Endocrinology & Metabolism, 105(8), 2752-2761.
[5] Berumen, J., Schmulson, M., Alegre-Díaz, J., Guerrero, G., Larriva-Sahd, J., Olaiz, G., Wong-Chew, R. M., Cantú-Brito, C., Ochoa-Guzmán, A., & Garcilazo-Ávila, A. (2020). Risk of infection and hospitalisation by Covid-19 in Mexico: a case-control study. medRxiv, 2020.2005. 2024.20104414.
[6] Calixto-Calderón, B., Vázquez-González, M. F., Martínez-Peláez, R., Bermeo-Escalona, J. R., García, V., Mena, L. J., Maestre, G., Parra-Michel, J. R., Ceja Bravo, L. A., & López-de-Alba, P. L. (2021). Pre-existing comorbidity is the highest risk factor for poor prognosis of COVID-19 among the Mexican population. Nova scientia, 13(SPE), 0-0.
[7] Chiquete, E., Alegre-Díaz, J., Ochoa-Guzmán, A., Toapanta-Yanchapaxi, L. N., González-Carballo, C., Garcilazo-Ávila, A., Santacruz-Benitez, R., Ramírez-Reyes, R., Wong-Chew, R. M., & Guerrero, G. (2022). Ethnicity and other COVID-19 death risk factors in Mexico. Archives of Medical Science: AMS, 18(3), 711.
[8] Denova‐Gutiérrez, E., Lopez‐Gatell, H., Alomia‐Zegarra, J. L., López‐Ridaura, R., Zaragoza‐Jimenez, C. A., Dyer‐Leal, D. D., Cortés‐Alcala, R., Villa‐Reyes, T., Gutiérrez‐Vargas, R., & Rodríguez‐González, K. (2020). The association of obesity, type 2 diabetes, and hypertension with severe coronavirus disease 2019 on admission among Mexican patients. Obesity, 28(10), 1826-1832.
[9] Escobedo-de la Peña, J., Rascón-Pacheco, R. A., de Jesús Ascencio-Montiel, I., González-Figueroa, E., Fernández-Gárate, J. E., Medina-Gómez, O. S., Borja-Bustamante, P., Santillán-Oropeza, J. A., & Borja-Aburto, V. H. (2021). Hypertension, diabetes and obesity are major risk factors for death in patients with COVID-19 in Mexico. Archives of medical research, 52(4), 443-449.
[10] Giannouchos, T. V., Sussman, R. A., Mier Odriozola, J. M., Poulas, K., & Farsalinos, K. (2020). Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. medRxiv, 2020.2006. 2004.20122481.
[11] Hernández-Vásquez, A., Azañedo, D., Vargas-Fernández, R., & Bendezu-Quispe, G. (2020). Association of comorbidities with pneumonia and death among COVID-19 patients in Mexico: a nationwide cross-sectional study. Journal of Preventive Medicine and Public Health, 53(4), 211.
[12] Martínez-Martínez, M. U., Alpízar-Rodríguez, D., Flores-Ramírez, R., Portales-Pérez, D. P., Soria-Guerra, R. E., Pérez-Vázquez, F., & Martinez-Gutierrez, F. (2022). An analysis of COVID-19 in Mexico: a prediction of severity. Journal of General Internal Medicine, 1-8.
[13] Martínez‐Murillo, C., Ramos Peñafiel, C., Basurto, L., Balcázar‐Hernández, L., Pellón, K., Flores López, E., Li Gómez, B., Ledesma, M. E., Rivera Tapia, R., & Madera Maldonado, E. (2021). COVID‐19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality. Endocrinology, Diabetes & Metabolism, 4(3), e00279.
[14] Martos-Benitez, F. D., Soler-Morejon, C. D., & Garcia-del Barco, D. (2021). Chronic comorbidities and clinical outcomes in patients with and without COVID-19: a large population-based study using Mexico's national administrative healthcare open data. Internal and emergency medicine, 16(6), 1507-1517.
[15] Najera, H., & Ortega-Avila, A. G. (2021). Health and institutional risk factors of COVID-19 mortality in Mexico, 2020. American journal of preventive medicine, 60(4), 471-477.
[16] Ñamendys-Silva, S. A., Alvarado-Ávila, P. E., Domínguez-Cherit, G., Rivero-Sigarroa, E., Sánchez-Hurtado, L. A., Gutiérrez-Villaseñor, A., Romero-González, J. P., Rodríguez-Bautista, H., García-Briones, A., & Garnica-Camacho, C. E. (2021). Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study. Heart & Lung, 50(1), 28-32.
[17] Parra-Bracamonte, G. M., Lopez-Villalobos, N., & Parra-Bracamonte, F. E. (2020). Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Annals of epidemiology, 52, 93-98. e92.
[18] Pizuorno, A., & Fierro, N. A. (2021). Latin America and chronic diseases: a perfect storm during the COVID-19 pandemic. Annals of Hepatology, 22, 100332.
[19] Salinas-Aguirre, J., Sánchez-García, C., Rodríguez-Sanchez, R., Rodríguez-Muñoz, L., Díaz-Castaño, A., & Bernal-Gómez, R. (2022). Clinical characteristics and comorbidities associated with mortality in patients with COVID-19 in Coahuila (Mexico). Revista Clínica Española (English Edition), 222(5), 288-292.
[20] Solís, P., & Carreño, H. (2020). COVID-19 fatality and comorbidity risk factors among diagnosed patients in Mexico. medRxiv, 2020.2004. 2021.20074591.
Villalpando, J. M. G., Forcelledo, H. A., Castillo, J. L. B., Sastré, A. J., Rojop, I. E. J., Hernández, V. O., Canabal, F. E. M., & Priego, C. G. G. (2022). COVID-19, long COVID syndrome, and mental health sequelae in a Mexican population. International journal of environmental research and public health, 19(12), 6970..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
